BioCentury | Aug 12, 2013
Finance

Abiding no more

Abiding no more Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus...
BC Week In Review | Dec 3, 2012
Clinical News

BD0801: Phase I started

Apexigen said partner Simcere began a Chinese Phase I trial of APX003. Apexigen declined to disclose details. Simcere has rights from Apexigen to develop and commercialize APX003 in China. Apexigen Inc. , Burlingame, Calif.   Simcere...
Items per page:
1 - 2 of 2